Category Archives: Parkinson’s Treatment

Parkinsons disease is a neurodegenerative disorder that affects predominantly dopamine-producing (dopaminergic) neurons in a specific area of the brain called substantia nigra. Dopamine plays a vital role in regulating the movement of the body. Continue reading →

UCB Parkinsons Disease Treatment Market Competitive Analysis: In addition, the projections offered in this report were derived using proven research assumptions and methods. In this way, the Parkinsons Disease Treatment research study offers a collection of information and analysis for every facet of the Parkinsons Disease Treatment market such as technology, regional markets, applications and types. The Parkinsons Disease Treatment market report also offers some market presentations and illustrations that include pie charts, diagrams and charts that show the percentage of different strategies implemented by service providers in the Parkinsons Disease Treatment market Continue reading →

Parkinson's, Alzheimer's disease and other brain disorders - The neurological manifestations of COVID-19 | &nbspPhoto Credit:&nbspiStock Images New Delhi: Amidst the COVID 19 pandemic the whole nation is under lockdown, and looking at the current situation of increasing cases, the situation is likely to continue. While most of the professionals have been instructed to work from home, being devoid of a workplace ambience can cause depression and anxiety among many and those with pre-existing conditions may be at an added risk of health problems. We are very well aware that social distancing is the only proven measure to break the infection chain in the present situation, people also need to keep themselves engaged in fruitful activities in order to keep their mental health intact. Continue reading →

The association between Cannabis sativa (cannabis) and psychosis is as old as its history. Continue reading →

EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI (amantadine) extended release capsules Continue reading →

UCB Parkinsons Disease Treatment Market: Competitive Landscape This section of the report provides complete information about the various manufacturers in the market. Continue reading →

Parkinsons disease is a condition that causes the brain to become progressively more damaged over time, said the NHS. You could be at risk of the neurodegenerative condition if you realise that you've been passing more urine than normal. Parkinson's is caused by a loss of nerve cells in a specific part of the brain. Continue reading →

Sunovion Pharma is calling it quits on dasotraline, a dopamine and norepinephrine reuptake inhibitor it was developing for binge eating disorder and attention deficit hyperactivity disorder (ADHD). It withdrew New Drug Applications for both indications and stopped development of the program. Sunovion, a subsidiary of Japanese pharma Sumitomo Dainippon, first filed dasotraline for approval in August 2017, for the treatment of ADHD in children, adolescents and adults Continue reading →

May 14, 2020 07:00 ET | Source: Prevail Therapeutics Phase 1/2 Trial of PR001 for Parkinsons Disease with GBA1 Mutations Ongoing; Study Startup Activities Progressing for Phase 1/2 Trials of PR001 for Type 2 NeuronopathicGaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Data Presentations Highlight Potential of AAV Gene Therapy Approach toSlow or Stop Neurodegenerative Disease Progression in Preclinical Models NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020. We are excited to continue the clinical development of PR001 and are on track to report interim data for a subset of patients from our Phase 1/2 clinical trial of PR001 for Parkinsons disease with GBA1 mutations (PD-GBA) later this year. Continue reading →

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., May 14, 2020 (GLOBE NEWSWIRE) Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2020 and highlighted recent progress across the companys clinical programs and pipeline of novel NMDA receptor modulators. Continue reading →